Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

2.

Studies on pyrazinoylguanidine. 7. Effects of single oral doses in normal human subjects.

Vesell ES, Beyer KH Jr.

Pharmacology. 1999 Mar;58(3):140-6.

PMID:
9925970
3.

Pyrazinoylguanidine in end-stage renal disease: a prospective, placebo-controlled pilot study.

Ahsan N, Korsunsky Z, Beyer KH Jr, Vesell ES.

Pharmacology. 1998 Aug;57(2):96-103.

PMID:
9691229
4.

Studies on pyrazinoylguanidine. 6. Prevention of cataracts in STZ-diabetic rats.

Follansbee MH, Beyer KH Jr, Vesell ES.

Pharmacology. 1997 May;54(5):256-60.

PMID:
9380771
5.

Studies on pyrazinoylguanidine. 5. Temporal effects over 24 weeks demonstrating attenuation of diabetic nephropathy in STZ-diabetic rats.

Follansbee MH, Beyer KH Jr, Griffith JW, Vesell ES.

Pharmacology. 1997 May;54(5):241-55.

PMID:
9380770
7.

Studies on pyrazinoylguanidine. 3. Downregulation of lipolysis in isolated adipocytes.

A-Rahim YI, Beyer KH Jr, Vesell ES.

Pharmacology. 1996 Oct;53(4):197-210.

PMID:
8958558
8.
9.

Studies on pyrazinoylguanidine. 1. Characterization of metabolic effects in diabetic rats.

A-Rahim YI, Beyer KH Jr, Vesell ES.

Pharmacology. 1996 Mar;52(3):135-44.

PMID:
8849482
10.

Pyrazinoylguanidine downregulates the glucose fatty-acid cycle in hypertensive, hyperinsulinemic diabetic patients.

Vesell ES, Chambers CE, Seaton TD, Passananti GT, Demers LM, Beyer KH Jr.

J Clin Pharmacol. 1994 Dec;34(12):1234-45.

PMID:
7738221
11.

Chlorothiazide. How the thiazides evolved as antihypertensive therapy.

Beyer KH.

Hypertension. 1993 Sep;22(3):388-91. No abstract available.

12.

Effects of pyrazinoylguanidine on the glucose-fatty acid cycle in normal subjects and patients with non-insulin-dependent diabetes mellitus.

Vesell ES, Chambers CE, Passananti GT, Demers LM, Beyer KH Jr.

J Clin Pharmacol. 1993 Sep;33(9):823-31.

PMID:
8227479
13.

Contrasting effects of pyrazinoylguanidine and hydrochlorothiazide in patients with renal insufficiency.

Beyer KH Jr, Ward TD, Vary JE, Gelarden RT, Knutson DW, Vesell ES.

J Clin Pharmacol. 1993 Jun;33(6):554-61.

PMID:
8366180
14.
15.

Pyrazinoylguanidine: antihypertensive, hypocholesterolemic, and renin effects.

Chambers CE, Vesell ES, Helm C, Passananti GT, Beyer KH Jr.

J Clin Pharmacol. 1992 Dec;32(12):1128-34.

PMID:
1487552
16.

Vitamin C and serendipity, fifty years ago.

Beyer KH Jr.

FASEB J. 1992 Nov;6(14):3316. No abstract available.

PMID:
1426769
17.

Inhibition of urea transport across renal tubules by pyrazinoylguanidine and analogs.

Beyer KH Jr, Gelarden RT, Vesell ES.

Pharmacology. 1992;44(3):124-38.

PMID:
1579595
18.

Pharmacokinetics of pyrazinoyl-guanidine, 3-aminopyrazinoyl-guanidine and their corresponding pyrazinoic acid metabolites in humans and dogs.

Passananti GT, Vesell ES, Jeszenka EV, Gelarden RT, Beyer KH Jr.

Pharmacology. 1992;45(3):129-41.

PMID:
1438523
19.

[Immunologic studies of benzodiazepine--the effect of structural characteristics on cross-reactivity].

Beyer KH, Martz S.

Arch Pharm (Weinheim). 1991 Nov;324(11):933-5. German.

PMID:
1804069
20.

Novel multivalent effects of pyrazinoylguanidine in patients with azotemia.

Beyer KH Jr, Gelarden RT, Vary JE, Brown LE, Vesell ES.

Clin Pharmacol Ther. 1990 May;47(5):629-38.

PMID:
2188773
21.

Metabolism of nafronyl in man.

Roth K, Hildebrand M, Beyer KH.

Eur J Drug Metab Pharmacokinet. 1989 Apr-Jun;14(2):133-8.

PMID:
2591417
22.

Active transport of urea by mammalian kidney.

Beyer KH Jr, Gelarden RT.

Proc Natl Acad Sci U S A. 1988 Jun;85(11):4030-1.

23.

[Fatal diltiazem poisoning].

Wiese J, Klug E, Schneider V, Tenczer J, Beyer KH.

Z Rechtsmed. 1988;100(4):271-6. German.

PMID:
3176717
24.

Fatal poisoning with selenium dioxide.

Köppel C, Baudisch H, Beyer KH, Klöppel I, Schneider V.

J Toxicol Clin Toxicol. 1986;24(1):21-35.

PMID:
3701906
25.

[Nifenazone, biotransformation in humans].

Beyer KH, Friese J.

Arch Pharm (Weinheim). 1985 Sep;318(9):855-63. German. No abstract available.

PMID:
2935118
26.

From theory to therapy: how to make a new drug out of a new idea.

Beyer KH Jr.

Clin Ther. 1985;7(6):652-8. No abstract available.

PMID:
4075360
27.

Metabolism of propallylonal.

Köppel C, Tenczer J, Beyer KH.

Arzneimittelforschung. 1985;35(8):1334-5.

PMID:
4074451
29.

[Diagnostic value of urine analysis in drug addicts and rehabilitation patients].

Baudisch H, Beyer KH, Köppel C, Lappenberg-Pelzer M, Lemm U, Riesselmann B.

Dtsch Med Wochenschr. 1983 Sep 30;108(39):1496-7. German. No abstract available.

PMID:
6617502
30.

Sustained concurrent blood pressure and salt/water balance in unrestrained rats.

Gill A, Beyer KH.

Pharmacology. 1983;26(6):303-12.

PMID:
6878423
31.

Hypertension: perspectives.

Beyer KH Jr, Peuler JD.

Pharmacol Rev. 1982 Dec;34(4):287-313. Review. No abstract available.

PMID:
6763701
32.

Diuretics in the 1980s.

Beyer KH Jr.

Clin Ther. 1982;5(1):3-5. No abstract available.

PMID:
7127367
33.

Chlorothiazide.

Beyer KH.

Br J Clin Pharmacol. 1982 Jan;13(1):15-24. No abstract available.

34.

Hydrochlorothiazide-induced 131I excretion facilitated by salt and water.

Beyer KH Jr, Fehr DM, Gelarden RT, White WJ, Lang CM, Vesell ES.

J Clin Pharmacol. 1981 May-Jun;21(5-6):201-12.

PMID:
7263913
35.

The cosmetic ingredient review: a status report.

Beyer KH Jr.

Clin Ther. 1981;4(1):2-6.

PMID:
7273066
36.

The pharmacological basis for modern diuretic therapy.

Beyer KH Jr.

Ration Drug Ther. 1978 Feb;12(2):1-5. No abstract available.

PMID:
644093
37.

Renal concentration gradients of salicylic acid and its metabolic congeners in the dog.

Beyer KH Jr, Gelarden RT.

Arch Int Pharmacodyn Ther. 1978 Feb;231(2):180-95.

PMID:
25632
39.

Diuretics in perspective.

Beyer KH Jr.

J Clin Pharmacol. 1977 Oct;17(10 Pt 2):618-25. No abstract available.

PMID:
915025
40.

[Pentazocine--an addiction problem? (author's transl)].

Kubicki S, Lenhard-Mazaheri P, Beyer KH.

MMW Munch Med Wochenschr. 1977 Aug 26;119(34):1069-74. German.

PMID:
408653
41.

Saluretic and uricosuric effects of (6, 7-dichloro-2-methyl=1-oxo-2-phenyl-5-indanyloxy) acetic acid (MK-196) in the chimpanzee.

Fanelli GM Jr, Bohn DL, Scriabine A, Beyer KH Jr.

J Pharmacol Exp Ther. 1977 Feb;200(2):402-12.

PMID:
14250
42.

A career or two.

Beyer KH Jr.

Annu Rev Pharmacol Toxicol. 1977;17:1-10. No abstract available.

PMID:
326157
43.

Discovery of the thiazides: where biology and chemistry meet.

Beyer KH Jr.

Perspect Biol Med. 1977 Spring;20(3):410-20. No abstract available.

PMID:
323815
44.

Haemoperfusion through activated charcoal in paraquat intoxication.

Solfrank G, Mathes GV, Clarmann M, Beyer KH.

Acta Pharmacol Toxicol (Copenh). 1977;41 Suppl 2:91-101. No abstract available.

PMID:
302630
45.

Effects of enzyme induction and inhibition on microsomal oxidation of 1,4-benzodiazepines.

Schwandt HJ, Sadée W, Beyer KH, Hilderbrandt AG.

Naunyn Schmiedebergs Arch Pharmacol. 1976 Jul;294(1):91-7.

PMID:
12479
46.

The pharmacological basis for modern diuretic therapy.

Beyer KH.

Nihon Jinzo Gakkai Shi. 1976 Jan;18(1):19-31. No abstract available.

PMID:
1035355
47.

Lessons from the discovery of modern diuretic therapy.

Beyer KH Jr.

Perspect Biol Med. 1976 Summer;19(4):500-8. No abstract available.

PMID:
958863
48.

Functional characteristics of the renal tubular secretion of amprolium, a quaternary organic base.

Beyer KH Jr, Gelarden RT.

J Pharmacol Exp Ther. 1975 Nov;195(2):194-200.

PMID:
241842
49.

The site and mode of action of some sulfonamide-derived diuretics.

Beyer KH Jr, Baer JE.

Med Clin North Am. 1975 May;59(3):735-50. No abstract available.

PMID:
1128017
50.

Editorial: Regarding the future of the national center for Toxicological Research.

Beyer KH Jr.

Toxicol Appl Pharmacol. 1975 Apr;32(1):1-4. No abstract available.

PMID:
1135864

Supplemental Content

Loading ...
Support Center